Insilico Medicine Unveils Revolutionary GIPR Antagonist ISM1354 for Weight Management

In a remarkable development within the pharmaceutical landscape, Insilico Medicine has put forward ISM1354, an innovative small molecule that targets the GIPR (glucose-dependent insulinotropic polypeptide receptor). This nomination aims to address obesity and related conditions such as type 2 diabetes, marking a significant stride in the field of metabolic health.

The Rationale Behind the Development

With the global population aging and the demand for effective weight management solutions increasing, the market for GLP-1 receptor agonists (GLP-1RAs) has seen unprecedented growth. This momentum is exemplified by the blockbuster sales of Tirzepatide, which reached $36.5 billion in 2025. The new strategic approach focusing on the combination of GIPR antagonists with GLP-1 therapies aims to enhance fat loss while preserving lean muscle mass, targeting a critical health issue—sarcopenia, especially prevalent among older adults.

However, as promising as this combined approach seems, earlier GIPR drug candidates faced significant hurdles during clinical trials, primarily due to safety concerns and toxicology issues. These challenges revealed the pressing need for refined molecules that could minimize risks while maximizing benefits.

A Breakthrough in Drug Discovery

Insilico Medicine, powered by generative AI technologies, has embraced this challenge by nominating ISM1354 as a preclinical candidate. According to Feng Ren, Co-CEO and Chief Scientific Officer, the rapid progress in drug discovery is largely attributed to the AI-powered Pharma.AI platform. This platform facilitated the efficient identification and optimization of viable GIPR antagonists—overcoming obstacles that have previously hindered drug development.

The development of ISM1354 not only holds the promise of treating obesity but also has potential applications in combating cardiovascular diseases linked to obesity, particularly heart failure. Notably, another GIPR antagonist, ISM0676, previously demonstrated a weight loss of up to 31.3% in combination therapies, showcasing the compound's impressive efficacy and the manner in which GIPR targets can enhance weight management strategies.

Pharmacokinetics and Safety Profile

In preclinical evaluations, ISM1354 exhibited exceptional pharmacokinetic properties across various species, achieving oral bioavailability ranging from 75% to 104%. Comparisons with benchmark compounds demonstrated ISM1354's superior plasma exposure and systemic advantages that could leverage its efficacy in clinical settings.

Moreover, an emphasis on safety was evident during in vitro studies, where ISM1354 showed lower inhibition of OATP1B1, indicating a safer profile concerning transporter-related interactions. With a significant hepatocyte safety margin—minimal effects on cell viability even at elevated concentrations—ISM1354 shows lower risk for hepatotoxicity compared to clinical-stage counterparts.

A Hopeful Future for Patients

The journey towards innovative treatments for obesity is not just a matter of weight loss; it embodies the aspiration for healthier living in an aging population. Alex Zhavoronkov, Co-CEO and Founder of Insilico Medicine, emphasizes that these advancements are paving the way for the emergence of GLP-1 therapies as foundational